Castleark Management LLC acquired a new position in shares of Cellebrite DI Ltd. (NASDAQ:CLBT - Free Report) in the fourth quarter, according to the company in its most recent disclosure with the SEC. The firm acquired 58,290 shares of the company's stock, valued at approximately $1,284,000.
Other hedge funds and other institutional investors have also modified their holdings of the company. True Wind Capital Management L.P. lifted its holdings in Cellebrite DI by 18.2% during the 4th quarter. True Wind Capital Management L.P. now owns 13,861,007 shares of the company's stock worth $305,358,000 after buying an additional 2,130,386 shares in the last quarter. FMR LLC raised its holdings in Cellebrite DI by 89.1% in the fourth quarter. FMR LLC now owns 10,621,344 shares of the company's stock valued at $233,988,000 after acquiring an additional 5,004,587 shares in the last quarter. Axon Enterprise Inc. purchased a new stake in shares of Cellebrite DI in the 4th quarter valued at approximately $198,270,000. Voss Capital LP raised its holdings in shares of Cellebrite DI by 1.2% in the 4th quarter. Voss Capital LP now owns 3,240,000 shares of the company's stock valued at $71,377,000 after purchasing an additional 39,700 shares in the last quarter. Finally, Pertento Partners LLP lifted its position in shares of Cellebrite DI by 26.7% during the 4th quarter. Pertento Partners LLP now owns 2,975,374 shares of the company's stock worth $65,547,000 after purchasing an additional 626,373 shares during the last quarter. 45.88% of the stock is currently owned by hedge funds and other institutional investors.
Wall Street Analyst Weigh In
CLBT has been the topic of several recent analyst reports. Lake Street Capital increased their target price on Cellebrite DI from $17.00 to $26.00 and gave the company a "buy" rating in a report on Friday, February 14th. Needham & Company LLC lowered their price objective on Cellebrite DI from $28.00 to $24.00 and set a "buy" rating for the company in a research report on Wednesday, May 14th. Finally, JPMorgan Chase & Co. dropped their price objective on Cellebrite DI from $29.00 to $25.00 and set an "overweight" rating on the stock in a report on Monday, May 12th. Seven research analysts have rated the stock with a buy rating, Based on data from MarketBeat, the stock currently has an average rating of "Buy" and an average target price of $22.43.
Check Out Our Latest Analysis on Cellebrite DI
Cellebrite DI Stock Performance
NASDAQ CLBT traded up $0.14 during trading hours on Tuesday, hitting $17.35. The company had a trading volume of 430,999 shares, compared to its average volume of 1,458,093. The business has a 50 day moving average of $18.88 and a 200-day moving average of $20.19. The company has a market cap of $4.16 billion, a PE ratio of -12.47, a price-to-earnings-growth ratio of 4.27 and a beta of 1.44. Cellebrite DI Ltd. has a 1-year low of $10.25 and a 1-year high of $26.30.
Cellebrite DI (NASDAQ:CLBT - Get Free Report) last announced its earnings results on Wednesday, May 14th. The company reported $0.10 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.09 by $0.01. The firm had revenue of $107.55 million during the quarter, compared to analysts' expectations of $109.36 million. Cellebrite DI had a positive return on equity of 58.70% and a negative net margin of 70.54%. The business's revenue was up 20.0% on a year-over-year basis. During the same period in the prior year, the firm earned $0.08 EPS. Sell-side analysts expect that Cellebrite DI Ltd. will post 0.3 earnings per share for the current fiscal year.
About Cellebrite DI
(
Free Report)
Cellebrite DI Ltd. develops solutions for legally sanctioned investigations in Europe, the Middle East, Africa, the Americas, and the Asia-Pacific. The company's DI suite of solutions allows users to collect, review, analyze, and manage digital data across the investigative lifecycle with respect to legally sanctioned investigations used in various cases, including child exploitation, homicide, anti-terror, border control, sexual crimes, human trafficking, corporate security, cryptocurrency, and intellectual property theft.
See Also
Before you consider Cellebrite DI, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Cellebrite DI wasn't on the list.
While Cellebrite DI currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Almost everyone loves strong dividend-paying stocks, but high yields can signal danger. Discover 20 high-yield dividend stocks paying an unsustainably large percentage of their earnings. Enter your email to get this report and avoid a high-yield dividend trap.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
